CompletedNCT01381419
Safety, Drug Levels and Brain Receptor Imaging of GSK1144814 in Healthy Adults
About this title
Read the official source — NCT01381419Medication studyAges 18–55United KingdomSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- HarrowSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: October 20, 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 21
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT01381419
- Official title
Show the full official title
A Single-blind, Randomised, Placebo-controlled, Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1144814 in Healthy Male and Female Subjects and an Open-label Positron Emission Tomography Study in Healthy Male Subjects to Evaluate the Neurokinin-1 (NK1) Receptor Occupancy of GSK1144814 in the Living Human Brain Using 11C GR205171.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Harrow
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including GSK1144814.
Who was this study for?
Listed age limits: 18 years to 55 years.
